Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial.
Talarico R, Italiano N, Emmi G, Piga M, Cantarini L, Mattioli I, Floris A, Gentileschi S, Di Cianni F, Urban ML, Chiara E, Marinello D, Del Bianco A, Figus M, Posarelli C, Fabiani C, Vagnani S, Andreozzi G, Lorenzoni V, Turchetti G, Cauli A, Emmi L, Salvarani C, Della Casa Alberighi O, Bombardieri S, Mosca M.
Talarico R, et al. Among authors: andreozzi g.
Ann Rheum Dis. 2024 Oct 17:ard-2024-226113. doi: 10.1136/ard-2024-226113. Online ahead of print.
Ann Rheum Dis. 2024.
PMID: 39419537
Free article.